GLP1RYour two copies: rs10305420C/rs10305420C
CCTypical response
The receptor that semaglutide and other GLP-1 drugs act on.
This result doesn't change the label.
Example report. Made from Leslie Knope's DNA data so you can see what yours will look like. Get your own report
Weight managementExample report
Tirzepatide
Mounjaro, Zepbound
Use with caution
Your GIPR gene raises your chance of nausea or vomiting on tirzepatide: roughly 4.4% of people with your genotype vomit, compared with about 2.5% at the lowest risk. Semaglutide is not affected by this gene.
The genes behind this label
The guidelines read 2 genes for tirzepatide. Each card shows the two copies this person inherited and what they mean.
GIPRYour two copies: rs1800437C/rs1800437G
Decreased function
One copy works and one works less well.
A gut-hormone receptor that tirzepatide and retatrutide act on.
This result changes the label.
What the guidelines say
What each guideline says about your result.
GLP1RTypical responseGIPRDecreased function
Gene2Rx research summary, both genes together
Evidence: moderateSee the drug page (Gene2Rx research summaries, opens in a new tab)
- In plain words
- Your GIPR gene raises your chance of nausea or vomiting on tirzepatide: roughly 4.4% of people with your genotype vomit, compared with about 2.5% at the lowest risk. Semaglutide is not affected by this gene.
- What it means
- GLP1R: the more common Pro7/Pro7 form of the signal peptide (rs10305420 C/C). GIPR: one copy of the Gln354 partial loss-of-function allele (rs1800437 G/C). Estimated risk of moderate-to-severe vomiting on tirzepatide is about 4.4% versus 2.5% for the lowest-risk genotype pair (odds ratio 1.8), and nausea about 17% versus 14%. Expected weight-loss efficacy from the GLP1R arm of tirzepatide. The GIPR component of this risk is specific to dual GIP/GLP-1 agonists and does not apply to semaglutide.
- What the research suggests
- Use standard dosing but consider a slower dose-escalation schedule, and counsel on the elevated chance of nausea and vomiting. If GI symptoms are intolerable, semaglutide is unaffected by the GIPR variant and may be better tolerated.
Gene2Rx guideline based on Su et al., Nature (2026), which linked GLP1R rs10305420 and GIPR rs1800437 to nausea and vomiting on tirzepatide. The GIPR effect was specific to tirzepatide and was not seen with semaglutide.
Gene2Rx reads your GLP1R and GIPR results together for tirzepatide, so this label reflects both genes.
About tirzepatide
Tirzepatide acts on two hormone receptors: the GLP-1 receptor, like semaglutide, and the GIP receptor.
- Used for
- Blood sugar control in type 2 diabetes; long-term weight reduction in obesity, or overweight with a weight-related condition; moderate to severe obstructive sleep apnea in adults with obesity
Others in weight management
Compare all 3 weight managementDon't change a dose on your own. Bring this report to your prescriber or pharmacist. They can weigh it with everything else they know about you.